Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 114

1.

A heterodimeric antibody fragment for passive immunotherapy against norovirus infection.

Yuki Y, Kurokawa S, Sato S, Sasou A, Matsumoto N, Suzuki A, Sakon N, Goda Y, Takeyama N, Miyoshi T, Marcotte H, Tanaka T, Hammarstrom L, Kiyono H.

J Infect Dis. 2020 Mar 25. pii: jiaa115. doi: 10.1093/infdis/jiaa115. [Epub ahead of print]

PMID:
32211769
2.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2020 Mar;25(3):e469-e476. doi: 10.1634/theoncologist.2019-0541. Epub 2019 Nov 20.

3.

Clinical efficacy of osimertinib for a patient with ileus due to peritoneal carcinomatosis.

Kawaguchi Y, Hanaoka J, Hayashi H, Fukuda Y, Iihara H, Suzuki A, Sugiyama T.

Clin Case Rep. 2020 Jan 3;8(2):347-350. doi: 10.1002/ccr3.2645. eCollection 2020 Feb.

4.

Efficacy and safety of 5 mg olanzapine combined with aprepitant, granisetron and dexamethasone to prevent carboplatin-induced nausea and vomiting in patients with gynecologic cancer: A multi-institution phase II study.

Iihara H, Shimokawa M, Hayasaki Y, Fujita Y, Abe M, Takenaka M, Yamamoto S, Arai T, Sakurai M, Mori M, Nakamura K, Kado N, Murase S, Shimaoka R, Suzuki A, Morishige KI.

Gynecol Oncol. 2020 Mar;156(3):629-635. doi: 10.1016/j.ygyno.2020.01.004. Epub 2020 Jan 9.

5.

Relationship Between Renal Function and the Incidence of Adverse Events in Patients With Colorectal Cancer Receiving Oxaliplatin.

Watanabe D, Fujii H, Yamada Y, Iihara H, Ishihara T, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A.

Anticancer Res. 2020 Jan;40(1):299-304. doi: 10.21873/anticanres.13953.

PMID:
31892580
6.

Implementation of a standardised pharmacist check of medical orders prior to preparation of anticancer drugs to reduce drug wastage.

Yamada H, Kobayashi R, Shimizu S, Yamada Y, Ishida M, Shimoda H, Kato-Hayashi H, Fujii H, Iihara H, Tanaka H, Suzuki A.

Int J Clin Pract. 2020 Apr;74(4):e13464. doi: 10.1111/ijcp.13464. Epub 2019 Dec 19.

PMID:
31830345
7.

Neutrophil Elastase Inhibition Ameliorates Endotoxin-Induced Myocardial Injury Accompanying Degradation of Cardiac Capillary Glycocalyx.

Fukuta T, Okada H, Takemura G, Suzuki K, Takada C, Tomita H, Suzuki A, Oda K, Uchida A, Matsuo S, Fukuda H, Yano H, Muraki I, Zaikokuji R, Kuroda A, Nishio A, Sampei S, Miyazaki N, Hotta Y, Yamada N, Watanabe T, Morishita K, Doi T, Yoshida T, Ushikoshi H, Yoshida S, Maekawa Y, Ogura S.

Shock. 2019 Nov 19. doi: 10.1097/SHK.0000000000001482. [Epub ahead of print]

PMID:
31764619
8.

Bevacizumab in Combination with TAS-102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study.

Fujii H, Matsuhashi N, Kitahora M, Takahashi T, Hirose C, Iihara H, Yamada Y, Watanabe D, Ishihara T, Suzuki A, Yoshida K.

Oncologist. 2019 Nov 20. pii: theoncologist.2019-0541. doi: 10.1634/theoncologist.2019-0541. [Epub ahead of print]

9.

Do SnI4 molecules deform on heating and pressurization in the low-pressure crystalline phase?

Naruta H, Fuchizaki K, Wakabayashi D, Suzuki A, Ohmura A, Saitoh H.

J Phys Condens Matter. 2020 Jan 30;32(5):055401. doi: 10.1088/1361-648X/ab4cbc. Epub 2019 Oct 10.

PMID:
31600736
10.

Adverse event profiles of ifosfamide-induced encephalopathy analyzed using the Food and Drug Administration Adverse Event Reporting System and the Japanese Adverse Drug Event Report databases.

Shimada K, Hasegawa S, Nakao S, Mukai R, Matsumoto K, Tanaka M, Uranishi H, Masuta M, Nishida S, Shimizu S, Hayashi Y, Suzuki A, Nakamura M.

Cancer Chemother Pharmacol. 2019 Nov;84(5):1097-1105. doi: 10.1007/s00280-019-03949-5. Epub 2019 Sep 9.

PMID:
31502115
11.

Optimal dose of sunitinib for long-term treatment in Japanese patients with renal cell carcinoma.

Yamada Y, Ohno Y, Kato Y, Kobayashi R, Hayashi H, Miyahara S, Nakane K, Mizutani K, Yokoi S, Fujii H, Iihara H, Ishihara T, Deguchi T, Sugiyama T, Suzuki A.

Cancer Chemother Pharmacol. 2019 Nov;84(5):987-992. doi: 10.1007/s00280-019-03935-x. Epub 2019 Sep 3.

PMID:
31482225
12.

Bergeyella zoohelcum isolated from oral cavities of therapy dogs.

Muramatsu Y, Haraya N, Horie K, Uchida L, Kooriyama T, Suzuki A, Horiuchi M.

Zoonoses Public Health. 2019 Dec;66(8):936-942. doi: 10.1111/zph.12644. Epub 2019 Aug 28.

PMID:
31464049
13.

Factors Enhancing Serum Syndecan-1 Concentrations: A Large-Scale Comprehensive Medical Examination.

Oda K, Okada H, Suzuki A, Tomita H, Kobayashi R, Sumi K, Suzuki K, Takada C, Ishihara T, Suzuki K, Kano S, Kondo K, Iwashita Y, Yano H, Zaikokuji R, Sampei S, Fukuta T, Kitagawa Y, Okamoto H, Watanabe T, Kawaguchi T, Kojima T, Deguchi F, Miyazaki N, Yamada N, Doi T, Yoshida T, Ushikoshi H, Yoshida S, Takemura G, Ogura S.

J Clin Med. 2019 Aug 27;8(9). pii: E1320. doi: 10.3390/jcm8091320.

14.

Comparative efficacy and safety of vancomycin versus teicoplanin in febrile neutropenic patients receiving hematopoietic stem cell transplantation.

Kato-Hayashi H, Niwa T, Ohata K, Harada S, Matsumoto T, Kitagawa J, Tsurumi H, Suzuki A.

J Clin Pharm Ther. 2019 Dec;44(6):888-894. doi: 10.1111/jcpt.13011. Epub 2019 Aug 1.

PMID:
31373043
15.

Effects of pharmacokinetics-related genetic polymorphisms on the side effect profile of afatinib in patients with non-small cell lung cancer.

Hayashi H, Iihara H, Hirose C, Fukuda Y, Kitahora M, Kaito D, Yanase K, Endo J, Ohno Y, Suzuki A, Sugiyama T.

Lung Cancer. 2019 Aug;134:1-6. doi: 10.1016/j.lungcan.2019.05.013. Epub 2019 May 18.

PMID:
31319966
16.

Clinical trial protocol of doublet therapy and olanzapine for carboplatin-induced nausea and vomiting in patients with thoracic cancer: a multicentre phase II trial.

Iihara H, Shimokawa M, Gomyo T, Fujita Y, Yoshida T, Funaguchi N, Minato K, Kaito D, Osawa T, Yamada M, Hirose C, Suzuki A, Ohno Y.

BMJ Open. 2019 Jul 4;9(7):e028056. doi: 10.1136/bmjopen-2018-028056.

17.

Evaluation of the Diabetes Regional Coordination Path using the Diabetes Coordination Notebook in community-based diabetes care.

Horikawa Y, Suzuki A, Hashimoto KI, Enya M, Nishida S, Kobayashi R, Ohashi T, Yamazaki F, Totani R, Kobayashi H, Yamamoto M, Itoh Y, Takeda J.

Diabetol Int. 2018 Oct 20;10(3):188-197. doi: 10.1007/s13340-018-0379-6. eCollection 2019 Jul.

18.

Enhancement of binding avidity by bivalent binding enables PrPSc-specific detection by anti-PrP monoclonal antibody 132.

Suzuki A, Yamasaki T, Hasebe R, Horiuchi M.

PLoS One. 2019 Jun 6;14(6):e0217944. doi: 10.1371/journal.pone.0217944. eCollection 2019.

19.

High total bilirubin level is a significant risk factor for severe neutropenia in patients receiving irinotecan-based chemotherapy.

Yamada Y, Fujii H, Ohata K, Kato-Hayashi H, Watanabe D, Ishihara T, Uemura S, Iwashita T, Imai H, Matsuhashi N, Takahashi T, Sugiyama T, Shimizu M, Yoshida K, Suzuki A.

Med Oncol. 2019 Jun 3;36(7):63. doi: 10.1007/s12032-019-1288-7.

PMID:
31161433
20.

Hydrous magnesium-rich magma genesis at the top of the lower mantle.

Nakajima A, Sakamaki T, Kawazoe T, Suzuki A.

Sci Rep. 2019 May 15;9(1):7420. doi: 10.1038/s41598-019-43949-2.

Supplemental Content

Loading ...
Support Center